Therapie primärer chronischer Kopfschmerzen: Chronische Migräne, chronischer Kopfschmerz vom Spannungstyp und andere chronische tägliche Kopfschmerzen

Zusammenfassung

Die IHS-Kriterien definieren vier primäre Kopfschmerzerkrankungen, die zu täglichen Dauerkopfschmerzen führen können: 1) chronische Migräne, 2) Kopfschmerz vom Spannungstyp, 3) Hemicrania continua, 4) neu aufgetretener Kopfschmerz. In der Praxis ist davon häufig der Kopfschmerz durch Medikamentenübergebrauch (früher: Analgetikakopfschmerz) abzugrenzen. Die jetzt von der Deutschen, Österreichischen und Schweizer Kopfschmerzgesellschaft gemeinsam vorgelegte Therapieleitlinie fasst die Literatur zur Therapie dieser Kopfschmerzformen zusammen und gibt Therapieempfehlungen, die die Literaturevidenz, aber auch die Praktikabilität berücksichtigen.

Summary

The IHS-criteria define four different primary headache syndromes with chronic daily headaches: 1) chronic migraine, 2) episodic and chronic tension type headache, 3) hemicrania continua, 4) new daily persisting headache. An important differential diagnosis is furthermore the medication overuse headache. The German, Austrian, and Swiss Headache societies present now the first joint guideline about the therapy of these headache syndromes. The current literature was reviewed and summarized. The therapy recommendations do not only include the scientific evidence but also the practical relevance.

Schlüsselwörter

Chronische Migräne - episodischer und chronischer Kopfschmerz vom Spannungstyp - Hemicrania continua - neu aufgetretener Kopfschmerz - Kopfschmerz bei Medikamentenübergebrauch - Therapieleitlinien

Keywords

Chronic migraine - episodic and chronic tension type headache - hemicrania continua - new daily persisting headache - medication overuse headache - guideline

• Literatur

• 1 Pfaffenrath V, Brune K, Diener HC, Gerber WD, Göbel H. Die Behandlung des Kopfschmerzes vom Spannungstyp. Therapieempfehlungen der Deutschen Migräne-und Kopfschmerzgesellschaft. Nervenheilkunde 1998; 17: 91-100.
• 2 Diener HC. (Hrsg). Leitlinien für Diagnostik und Therapie in der Neurologie. 3. aktualisierte und erweiterte Auflage. Stuttgart: Thieme; 2005
• 3 Olesen J, Bousser M-G, Diener H. et al. The International Classification of Headache Disorders. 2^nd Edition. Cephalalgia 2004; 24 (Suppl. 01) 1-160.
• 4 Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurology 2004; 08: 475-483.
• 5 May A, Straube A, Peikert A, Diener H. Diagnostik und apparative Zusatzuntersuchungen bei Kopfschmerzen. In: Leitlinien für Diagnostik und Therapie in der Neurologie. Diener H. (Hrsg) Stuttgart: Thieme; 2005: 476-479.
• 6 Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches. Field trial of revised IHS criteria. Neurology 1996; 47: 871-875.
• 7 Silberstein SD, Lipton RB. Chronic daily headache. Curr Opin Neurol 2000; 13 (03) 277-283.
• 8 Mitsikostas DD, Tsaklakidou D, Athanasiadis N, Thomas A. The prevalence of headache in Greece: correlations to latitude and climatological factors. Headache 1996; 36 (03) 168-173.
• 9 Pascual J, Colas R, Castillo J. Epidemiology of chronic daily headache. Curr Pain Headache Rep 2001; 05: 529-536.
• 10 Colas R, Munoz P, Temprano R, Gomez C, Pascual J. Chronic daily headache with analgesic overuse: epidemiology and impact on quality of life. Neurology 2004; 62 (08) 1338-1342.
• 11 Láinez MJA, Monzón MJ. Chronic daily headache. Current Neurology and Neuroscience Reports 2001; 01: 118-124.
• 12 Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 2003; 106 1-2 81-9.
• 13 Zwart JA, Dyb G, Hagen K, Svebak S, Holmen J. Analgesic use: a predictor of chronic pain and medication overuse headache: the Head-HUNT Study. Neurology 2003; 61 (02) 160-4.
• 14 Zwart JA, Dyb G, Hagen K, Svebak S, Stovner LJ, Holmen J. Analgesic overuse among subjects with headache, neck, and low-back pain. Neurology 2004; 62 (09) 1540-4.
• 15 Katsarava Z, Schneeweiss S, Kurth T, Kroener U, Fritsche G, Eikermann A, Diener HC, Limmroth V. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 2004; 62 (05) 788-790.
• 16 Wang SJ, Fuh JL, Lu SR, Juang KD. Chronic daily headache in adolescents: prevalence, impact, and medication overuse. Neurology 2006; 66 (02) 193-197.
• 17 Dyb G, Holmen TL, Zwart JA. Analgesic overuse among adolescents with headache: the Head-HUNT-Youth Study. Neurology 2006; 66 (02) 198-200.
• 18 Juang K-D, Wang S-J, Fuh J-L, Lu S-R, Su T-P. Comorbidity of depressive and anxiety disorders in chronic daily headache and its subtypes. Headache 2000; 40: 818-823.
• 19 Radat F, Swendsen J. Psychiatric comorbidity in migraine: a review. Cephalalgia 2005; 25 (03) 165-78.
• 20 Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Gobel H, Lainez MJ, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Silberstein SD, Steiner TJ. for the Headache Classification Committee. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26 (06) 742-746.
• 21 de Tommaso M, Losito L, Difruscolo O, Libro G, Guido M, Livrea P. Changes in cortical processing of pain in chronic migraine. Headache 2005; 45 (09) 1208-1218.
• 22 Aurora SK, Barrodale P, Chronicle EP, Mulleners WM. Cortical inhibition is reduced in chronic and episodic migraine and demonstrates a spectrum of illness. Headache 2005; 45 (05) 546-552.
• 23 Diener HC. Therapie der Migräneattacke und Migräneprophylaxe. In: Leitlinien für Diagnostik und Therapie in der Neurologie. Diener H. (Hrsg). Stuttgart: Thieme; 2005
• 24 Dowson AJ, Dodick DW, Limmroth V. Medication overuse headache in patients with primary headache disorders: epidemiology, management and pathogenesis. CNS Drugs 2005; 19 (06) 483-97.
• 25 Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia 2003; 23 (08) 820-4 Spears RC. Hemicrania continua: a case in which a patient experienced complete relief on melatonin. Headache 2006; 46(03): 524-527.
• 26 Rothrock JF, Parada VA, Drinkard R, Zweifler RM, Key KF. Predictors ofa negative response to topiramate therapy in patients with chronic migraine. Headache 2005; 45 (07) 932-935.
• 27 Mathew NT, Kailasam J, Meadors L. Prophylaxis of migraine, transformed migraine, and cluster headache with topiramate. Headache 2002; 42 (08) 796-803.
• 28 Bartolini M, Silvestrini M, Taffi R, Lanciotti C, Luconi R, Capecci M, Provinciali L. Efficacy of topiramate and valproate in chronic migraine. Clin Neuropharmacol 2005; 28 (06) 277-279.
• 29 Diener H, Bussone G, Van Oene J, Lahaye M, Schwalen S, Goadsby P. Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia in press.
• 30 Rothrock J. Management of chronic daily headache utilizing a uniform treatment pathway. Headache 1999; 39: 650-653.
• 31 Freitag FG, Diamond S, Diamond ML, Urban GJ. Divalproex in the long-term treatment of chronic daily headache. Headache 2001; 41 (03) 271-278.
• 32 Tomkins GE, Jackson JL, O’Malley PG, Balden E, Santoro JE. Treatment of chronic headache with antidepressants: a meta-analysis. Am J Med 2001; 111 (01) 54-63.
• 33 Matharu MS, Bartsch T, Ward N, Frackowiak RS, Weiner R, Goadsby PJ. Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain 2004; 127: 220-30.
• 34 Mauskop A. Vagus nerve stimulation relieves chronic refractory migraine and cluster headaches. Cephalalgia 2005; 25 (02) 82-6.
• 35 Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C. BOTOX CDH Study Group. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005; 45 (04) 293-307.
• 36 Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD. BOTOX CDH Study Group. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 2005; 45 (04) 315-24.
• 37 Ciancarelli I, Tozzi-Ciancarelli MG, Di Massimo C, Olivieri L, Carolei A. Preventive non-pharmacological treatment and nitric oxide in chronic migraine. J Headache Pain 2005; 06 (04) 341-2.
• 38 Penzien DB, Rains JC, Lipchik GL, Nicholson RA, Lake 3rd AE, Hursey KG. Future directions in behavioural headache research: applications for an evolving health care environment. Headache 2005; 45 (05) 526-534.
• 39 Karli N, Zarifoglu M, Calisir N, Akgoz S. Comparison of pre-headache phases and trigger factors of migraine and episodic tension-type headache: do they share similar clinical pathophysiology?. Cephalalgia 2005; 25 (06) 444-451.
• 40 Ulrich V, Gervil M, Olesen J. The relative influence of environment and genes in episodic tension-type headache. Neurology 2004; 62 (11) 2065-2068.
• 41 Jensen R. Pathophysiological mechanisms of tension-type headache: a review of epidemiological and experimental studies. Cephalalgia 1999; 19: 602-621.
• 42 Christensen MB, Bendtsen L, Ashina M, Jensen R. Experimental induction of muscle tenderness and headache in tension-type headache patients. Cephalalgia 2005; 25 (11) 1061-1067.
• 43 Ashina S, Bendtsen L, Ashina M. Pathophysiology of tension-type headache. Curr Pain Headache Rep 2005; 09 (06) 415-422.
• 44 Holzhammer J, Wöber C. Alimentäre Triggerfaktoren bei Migräne und Kopfschmerz vom Spannungstyp. Schmerz 206; 20: 151-159.
• 45 Martínez-Martín P, Raffaelli E, Titus F. et al. Efficacy and safety of metamizol vs. Acetylsalicylic acid in patients with moderate episodic tensiontype headache: a randomized, double-blind, placebo-and active-controlled, multicentre study. Cephalalgia 2001; 21: 604-610.
• 46 Haag G, Evers S, May A, Neu IS, Vivell W, Ziegler A. Selbstmedikation bei Migräne und Kopfscherzen vom Spannungstyp. Evidenzbasierte Empfehlungen der Deutschen Migräne-und Kopfschmerz-Gesellschaft (DMKG). Nervenheilkunde 2004; 23: 415-430.
• 47 Cerbo R, Barbanti P, Fabbrini G, Pascali MP, Catarci T. Amitriptyline is effective in chronic but not in episodic tension-type headache: pathogenetic implications. Headache 1998; 38 (06) 453-457.
• 48 White AR, Resch KL, Chan JC, Norris CD, Modi SK, Patel JN, Ernst E. Acupuncture for episodic tension-type headache:a multicentre randomized controlled trial. Cephalalgia 2000; 20: 632-637.
• 49 Bronfort G, Nilsson N, Haas M, Evans R, Goldsmith CH, Assendelft WJ, Bouter LM. Non-invasive physical treatments for chronic/recurrent headache. Cochrane Database Syst Rev 2004; 03: CD001878.
• 50 Verhagen AP, Damen L, Berger MY, Passchier J, Merlijn V, Koes BW. Conservative treatments of children with episodic tension-type headache. A systematic review. J Neurol 2005; 252 (10) 1147-1154.
• 51 Russell MB, Ostergaard S, Bendtsen L, Olesen J. Familial occurrence of chronic tension-type headache. Cephalalgia 1999; 19 (04) 207-210.
• 52 Spierings ELH, Ranke AH, Schroevers M, Honkoop PC. Chronic daily headache: a time perspective. Headache 2000; 40: 306-310.
• 53 Breslau N, Schultz LR, Stewart WF, Lipton RB, Lucia VC, Welch KMA. Headache and major depression. Is the association specific to migraine? Neurology 2000; 54: 308-313.
• 54 Bendtsen L. Central sensitization in tension-type headache-possible pathophysiological mechanisms. Cephalalgia 2000; 20: 486-508.
• 55 Ashina M, Lassen LH, Bendtsen L, Jensen R, Olesen J. Effect of inhibition of nitiric oxide synthase on chronic tension-type headache: a randomised crossover trial. Lancet 1999; 353: 287-289.
• 56 Jensen R, Olesen J. Tension-type headache: an update on mechanisms and treatment. Cur Opin Neurol 2000; 13: 285-289.
• 57 Ashina M. Neurobiology of chronic tension-type headache. Cephalalgia 2004; 24 (03) 161-72.
• 58 Fernandez-de-Las-Penas C, Alonso-Blanco C, Cuadrado ML, Gerwin RD, Pareja JA. Myofascial trigger points and their relationship to headache clinical parameters in chronic tension-type headache. Headache 2006; 46 (08) 1264-72.
• 59 Makowska A, Panfil C, Ellrich J. Nerve growth factor injection into semispinal neck muscle evokes sustained facilitation of the jaw-opening reflex in anesthetized mice --possible implications for tension-type headache. Exp Neurol 2005; 191 (02) 301-9.
• 60 Makowska A, Panfil C, Ellrich J. Long-term potentiation of orofacial sensorimotor processing by noxious input from the semispinal neck muscle in mice. Cephalalgia 2005; 25 (02) 109-16.
• 61 Panfil C, Makowska A, Ellrich J. Brainstem and cervical spinal cord Fos immunoreactivity evoked by nerve growth factor injection into neck muscles in mice. Cephalalgia 2006; 26 (02) 128-35.
• 62 Schmidt-Wilcke T, Leinisch E, Straube A, Kampfe N, Draganski B, Diener HC, Bogdahn U, May A. Gray matter decrease in patients with chronic tension type headache. Neurology 2005; 65 (09) 1483-1486.
• 63 Hannerz J, Jogestrand T. Is chronic tensiontype headache a vascular headache? The relation between chronic tension-type headache and cranial hemodynamics. Headache 1998; 38: 668-675.
• 64 Hannerz J, Schnell PO, Larsson S, Jacobsson H. Blood pool scintigraphy of the skull in relation to head-down tilt provocation in patients with chronic tension-type headache and controls. Headache 2004; 44 (03) 223-9.
• 65 Silberstein SD, Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Gobel H, Lainez MJ, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Steiner TJ. International Headache Society. The International Classification of Headache Disorders, 2nd Edition (ICHD-II)--revision of criteria for 8.2 Medication-overuse headache. Cephalalgia 2005; 25 (06) 460-5.
• 66 Holroyd KA, O’Donnell FJ, Stensland M, Lipchik GL, Cordingley GE, Carlson BW. Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy and their combination. JAMA 2001; 285: 2208-2215.
• 67 Redillas C, Solomon S. Prophylactic pharmacological treatment of chronic daily headache. Headache 2000; 40: 83-102.
• 68 Ashina S, Bendtsen L, Jensen R. Analgesic effect of amitriptyline in chronic tension-type headache is not directly related to serotonin reuptake inhibition. Pain 2004; 108 1-2 108-14.
• 69 Pfaffenrath V, Diener HC, Isler H, Meyer C, Scholz E, Taneri Z, Wessely P, Zaiser-Kaschel H, Haase W, Fischer W. Efficacy and tolerability of amitriptylinoxide in the treatment of chronic tension-type headache: a multicentre controlled study. Cephalalgia 1994; 14 (02) 149-55.
• 70 Holroyd KA, Labus JS, O’Donnell FJ, Cordingley GE. Treating chronic tension-type headache not responding to amitriptyline hydrochloride with paroxetine hydrochloride: a pilot evaluation. Headache 2003; 43 (09) 999-1004.
• 71 Moja PL, Cusi C, Sterzi RR, Canepari C. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev 2005; 03: CD002919.
• 72 Fogelholm R, Murros K. Tizanidine in chronic tension-type headache: a placebo controlled, double-blind cross over study. Headache 1992; 32: 509-513.
• 73 Murros K, Kataja M, Hedman C, Havanka H, Sako E, Farkkila M, Peltola J, Keranen T. Modified-release formulation of tizanidine in chronic tension-type headache. Headache 2000; 40: 633-637.
• 74 Vernon H, McDermaid CS, Hagino C. Systematic review of randomized clinical trials of complementary/alternative therapies in the treatment of tension-type and cervicogenic headache. Complementary Therapies in Medicine 1999; 07: 142-155.
• 75 Bendtsen L, Jensen R. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. Neurology 2004; 62 (10) 1706-11.
• 76 Langemark M, Olesen J. Sulpiride and paroxetine in the treatment of chronic tension-type headache. An explanatory double-blind trial. Headache 1994; 34 (01) 20-4.
• 77 Spira PJ, Beran RG. Australian Gabapentin Chronic Daily Headache Group. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology 2003; 61 (12) 1753-9.
• 78 Lampl C, Marecek S, May A, Bendtsen L. A prospective, open-label, long-term study of the efficacy and tolerability of topiramate in the prophylaxis of chronic tension-type headache. Cephalalgia 2006; 26 (10) 1203-8.
• 79 Robbins L. Long-acting opioids for severe chronic daily headache. Headache Q 1999; 10: 135-139.
• 80 Saper JR, Lake 3rd AE, Hamel RL, Lutz TE, Branca B, Sims DB, Kroll MM. Daily scheduled opioids for intractable head pain: long-term observations of a treatment program. Neurology 2004; 62 (10) 1687-94.
• 81 Bettucci D, Testa L, Calzoni S, Mantegazza P, Viana M, Monaco F. Combination of tizanidine and amitriptyline in the prophylaxis of chronic tension-type headache: evaluation of efficacy and impact on quality of life. J Headache Pain 2006; 07 (01) 34-6.
• 82 Rampello L, Alvano A, Chiechio S, Malaguarnera M, Raffaele R, Vecchio I, Nicoletti F. Evaluation of the prophylactic efficacy of amitriptyline and citalopram, alone or in combination, in patients with comorbidity of depression, migraine, and tension-type headache. Neuropsychobiology 2004; 50 (04) 322-8.
• 83 Bernstein DA, Borkovec TD. Entspannungstraining. Handbuch der Progressiven Muskelrelaxation. München: Pfeiffer; 1975
• 84 Larsson B, Andrasik F. Relaxation treatment of recurrent headaches in children and adolescents. In: Headaches and migraine in Childhood and Adolescence. Guidetti V, Russell G, Sillanpää M, Winner P. (eds). London, UK: Martin Dunitz; 2002: 307-316.
• 85 Andrasik F, Walch SE. Headaches. In: Handbook of Psychology. Vol 9. Nezu AM, Nezu CM, Geller PA. (eds). New York: Wiley; 2003: 245-266.
• 86 Harpole LH, Samsa GP, Jurgelski AE, Shipley JL, Bernstein A, Matchar DB. Headache management program improves outcome for chronic headache. Headache 2003; 43: 715-723.
• 87 Andrasik F, Lords AO. Biofeedback. Mosby´s Complementary & Alternative Medicine:a Research-Based Approach. Second Edition. St. Louis: Mosby; 2004
• 88 Sarafino EP, Goehring P. Age comparisons in acquiring biofeedback control and success in reducing headache pain. Ann Behav Med 2000; 22: 10-16.
• 89 Penzien DB, Rains JC, Andrasik F. Behavioral management of recurrent headache: Three decades of experience and empiricism. Applied Psychophysiology and Biofeedback 2002; 27: 163-181.
• 90 Torelli P, Jensen R, Olesen J. Physiotherapy for tension-type headache: a controlled study. Cephalalgia 2004; 24 (01) 29-36.
• 91 Evers S, Rahmann A, Vollmer-Haase J, Husstedt IW. Treatment of headache with botulinum toxin A--a review according to evidence-based medicine criteria. Cephalalgia 2002; 22 (09) 699-710.
• 92 Schulte-Mattler WJ, Krack P. BoNTTH Study Group. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain 2004; 109 (1-2): 110-4.
• 93 Vickers AJ, Rees RW, Zollman CE, McCarney R, Smith CM, Ellis N, Fisher P, Van Haselen R. Acupuncture for chronic headache in primary care: large, pragmatic, randomised trial. BMJ 2004; 328 7442 744.
• 94 Melchart D, Streng A, Hoppe A, Brinkhaus B, Witt C, Wagenpfeil S, Pfaffenrath V, Hammes M, Hummelsberger J, Irnich D, Weidenhammer W, Willich SN, Linde K. Acupuncture in patients with tension-type headache: randomised controlled trial. BMJ 2005; 331 7513 376-82.
• 95 Coeytaux RR, Kaufman JS, Kaptchuk TJ, Chen W, Miller WC, Callahan LF, Mann JD. A randomized, controlled trial of acupuncture for chronic daily headache. Headache 2005; 45 (09) 1113-23.
• 96 Evers S, Pothmann R, Überall M, Naumann E, Gerber W-D. Therapie idiopathischer Kopfschmerzen im Kindesalter. Empfehlungen der Deutschen Migräne-und Kopfschmerzgesellschaft. Nervenheilkunde 2001; 20: 306-315.
• 97 Peres MF, Silberstein SD, Nahmias S, Shechter AL, Youssef I, Rozen TD, Young WB. Hemicrania continua is not that rare. Neurology 2000; 57 (06) 948-51.
• 98 Newman LC, Spears RC, Lay CL. Hemicrania continua: a third case in which attacks alternate sides. Headache 2004; 44 (08) 821-823.
• 99 Matharu MS, Bradbury P, Swash M. Hemicrania continua: side alternation and response to topiramate. Cephalalgia 2006; 26 (03) 341-344.
• 100 Sjaastad O, Stovner LJ, Stolt ANielsen, Antonaci F, Fredriksen TA. CPH and hemicrania continua: requirements of high indomethacin dosages--an ominous sign?. Headache 1995; 35 (06) 363-367.
• 101 Pareja JA, Vincent M, Antonaci F, Sjaastad O. Hemicrania continua: diagnostic criteria and nosologic status. Cephalalgia 2001; 21 (09) 874-877.
• 102 Hannerz J. Chronic bilateral headache responding to indomethazin. Headache 2000; 40: 840-843.
• 103 Lay CL, Newman LC. Posttraumatic hemicrania continua. Headache 1999; 39 (04) 275-279.
• 104 Levy MJ, Matharu MS, Meeran K, Powell M, Goadsby PJ. The clinical characteristics of headache in patients with pituitary tumours. Brain 2005; 128: 1921-30.
• 105 Vikelis M, Xifaras M, Magoufis G, Gekas G, Mitsikostas DD. Headache attributed to unruptured saccular aneurysm, mimicking hemicrania continua. J Headache Pain 2005; 06 (03) 156-158.
• 106 Rogalewski A, Evers S. Symptomatic hemicrania continua after internal carotid artery dissection. Headache 2005; 45 (02) 167-9.
• 107 Matharu MS, Cohen AS, McGonigle DJ, Ward N, Frackowiak RS, Goadsby PJ. Posterior hypothalamic and brainstem activation in hemicrania continua. Headache 2004; 44 (08) 747-6.
• 108 Spears RC. Hemicrania continua: a case in which a patient experienced complete relief on melatonin. Headache 2006; 46 (03) 524-7.
• 109 Rajabally YA, Jacob S. Hemicrania continua responsive to verapamil. Headache 2005; 45 (08) 1082-1083.
• 110 Lanteri-Minet M, Auray JP, El Hasnaoui A, Dartigues JF, Duru G, Henry P, Lucas C, Pradalier A, Chazot G, Gaudin AF. Prevalence and description of chronic daily headache in the general population in France. Pain 2003; 102 1-2 143-149.
• 111 Chakravarty A. Chronic daily headaches: clinical profile in Indian patients. Cephalalgia 2003; 23 (05) 348-53.
• 112 Li D, Rozen TD. The clinical characterisation of new daily persistent headache. Cephalalgia 2002; 22: 66-69.
• 113 Silberstein SD, Lipton RB, Solomon S, Mathew NT. Classification of daily and near daily headaches: proposed revisions to the IHS-criteria. Headache 1994; 34: 1-7.
• 114 Vanast WJ, Diaz-Mitoma F, Tyrrell DL. Hypothesis: chronic benign daily headache is an immune disorder with a viral trigger. Headache 1987; 27 (03) 138-42.
• 115 Diaz-Mitoma F, Vanast WJ, Tyrrell DL. Increased frequency of Epstein-Barr virus excretion in patients with new daily persistent headaches. Lancet 1987; 21 1(8530): 411-5.
• 116 Hamada T, Ohshima K, Ide Y, Sakato S, Takamori M. A case of new daily persistent headache with elevated antibodies to Epstein-Barr virus. Jpn J Med 1991; 30 (02) 161-3.
• 117 Mack KJ. What incites new daily persistent headache in children?. Pediatr Neurol 2004; 31 (02) 122-5.
• 118 Goadsby PJ, Boes C. New daily persistent headache. J Neurol Neurosurg Psychiat 2002; 72 (Suppl. 02) ii6-ii9.
• 119 Rozen TD. New daily persistent headache. Curr Pain Headache Rep 2003; 07 (03) 218-23.
• 120 Evans RW, Rozen TD. Etiology and treatment of new daily persistent headache. Headache 2001; 41 (08) 830-832.
• 121 Evans RW. New daily persistent headache. Curr Pain Headache Rep 2003; 07: 3003-3007.
• 122 Vanast WJ. New daily persistent headaches definition of a benign syndrome. Headache 1986; 26: 318.
• 123 Paemeleire K, Bahra A, Evers S, Matharu MS, Goadsby PJ. Medication-overuse headache in patients with cluster headache. Neurology 2006; 67 (01) 109-13.
• 124 Fuh JL, Wang SJ, Lu SR, Juang KD. Does medication overuse headache representa behavior of dependence?. Pain 2005; 119 1-3 49-55.
• 125 Radat F, Creac’h C, Swendsen JD, Lafittau M, Irachabal S, Dousset V, Henry P. Psychiatric comorbidity in the evolution from migraine to medication overuse headache. Cephalalgia 2005; 25 (07) 519-22.
• 126 Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener HC. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002; 59 (07) 1011-4.
• 127 Fumal A, Laureys S, Di Clemente L, Boly M, Bohotin V, Vandenheede M, Coppola G, Salmon E, Kupers R, Schoenen J. Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. Brain 2006; 129 (Pt 2): 543-50.
• 128 Ayzenberg I, Obermann M, Nyhuis P, Gastpar M, Limmroth V, Diener HC, Kaube H, Katsarava Z. Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures. Cephalalgia 2006; 26 (09) 1106-1114.
• 129 Relja G, Granato A, Bratina A, Antonello R, Zorzon M. Outcome of medication overuse headache after abrupt in-patient withdrawal. Cephalalgia 2006; 26 (05) 589-95.
• 130 Katsarava Z, Fritsche G, Muessig M, Diener HC, Limmroth V. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001; 57 (09) 1694-8.
• 131 Coskun O, Ucler S, Cavdar L, Inan LE. Effect of valproic acid on withdrawal therapy in patients with overuse of chronic daily headache medications. J Clin Neurosci. 2006 epub ahead of print.
• 132 Zeeberg P, Olesen J, Jensen R. Probable medication-overuse headache. Neurology 2006; 66: 1-5.
• 133 Descombes S, Brefel-Courbon C, Thalamas C, Albucher JF, Rascol O, Montastruc JL, Senard JM. Amitriptyline treatment in chronic drug-induced headache: a double-blind comparative pilot study. Headach 2001; 41: 178-182.
• 134 Katsarava Z, Limmroth V, Finke M, Diener HC, Fritsche G. Rates and predictors for relapse in medication overuse headache: a 1-year prospective study. Neurology 2003; 60 (10) 1682-3.
• 135 Suhr B, Evers S, Bauer B, Gralow I, Grotemeyer KH, Husstedt IW. Drug-induced headache: longterm results of stationary versus ambulatory withdrawal therapy. Cephalalgia 1999; 19 (01) 44-9.
• 136 Fritsche G, Eberl A, Katsarava Z, Limmroth V, Diener HC. Drug-induced headache: long-term follow-up of withdrawal therapy and persistence of drug misuse. Eur Neurol 2001; 45: 229-235.
• 137 Grazzi L, Andrasik F, D’Amico D, Leone M, Usai S, Kass SJ, Bussone G. Behavioral and pharmacologic treatment of transformed migraine with analgesic overuse: outcome at 3 years. Headache 2002; 42: 483-490.
• 138 Krymchantowski AV, Moreira PF. Out-patient detoxification in chronic migraine: comparison of strategies. Cephalalgia 2003; 23 (10) 982-993.